Bristol-Myers Squibb Company operates as a global biopharmaceutical enterprise, actively involved in the discovery, development, manufacturing, and commercialization of innovative medicines across the world. Its portfolio addresses a wide range of therapeutic areas, including hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and COVID-19. Among its key offerings, the company provides Revlimid and Pomalyst/Imnovid, both immunomodulatory drugs crucial for treating multiple myeloma.